Treatment currently relies on inhibitors of SGLT2, the renal sodium‐glucose co‐transporter, which indirectly enhances urinary excretion of 1,5‐anhydroglucitol (1,5‐AG), the precursor of the toxic 1,5‐AG6P that accumulates in neutrophils and is at the origin of these patients' neutropenia. Here, SLC5A2 is linked to neutropenia.